Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells.

@article{Ajana2009ArsthinolNP,
  title={Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells.},
  author={Imane Ajana and Alain Astier and St{\'e}phane Gibaud},
  journal={The Journal of pharmacy and pharmacology},
  year={2009},
  volume={61 10},
  pages={1295-301}
}
OBJECTIVES The organoarsenical arsthinol was used in the 1950s in the treatment of amoebiasis and yaws and was considered as 'highly tolerated'. The aim of this work was to study its anti-leukaemic activity and to develop nanosuspensions of the drug, thereby limiting brain concentrations and the risk of encephalopathy. METHODS Arsthinol nanosuspensions were produced by high-pressure homogenization. The anti-leukaemic activity was assessed on NB4 acute promyelocytic leukaemia cells (vs… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
4 Extracted Citations
41 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 41 references

2-Phenyl-[1, 3, 2] dithiarsolan-4-yl)-methanol derivatives show in vitro antileukemic activity

  • S Gibaud
  • J Organomet Chem
  • 2006
Highly Influential
4 Excerpts

Use of organoarsenic or organoantimony derivatives for their anticancer properties

  • A Astier, S. Gibaud
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…